Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors

Wyngaert, Tim Van den; Delforge, Michel; Doyen, Chantal; Duck, Lionel; Wouters, Kristien; Delabaye, I; Wouters, Carine; Wildiers, Hans

doi:10.1007/s00520-013-1934-0

Cited by 19 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, studies showed that persistent, monthly use of BPs for more than 18 months was associated with a 50% lower risk of SREs compared with persistent, monthly use of BPs for less than 3 months in breast cancer patients with bone metastases [ 28 ]. In addition, even for patients with solid tumors who already received BP treatment for at least 2 years, the persistent use of BPs for an additional 18 months was associated with a lower SRE risk (hazard ratio = 0.42, P = 0.01) [ 29 ]. Our survey also showed that the persistent use of BPs for more than 6 months could significantly prolong the time to the first SRE compared with the use of BPs for less than 6 months.…”

Section: Discussionmentioning

confidence: 99%

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Yang

Jin

et al. 2016

Chin J Cancer

View full text Add to dashboard Cite

BackgroundBone metastases are common in patients with advanced cancer. Bisphosphonates (BPs) could prevent or delay the development of skeleton-related events (SREs). The present study aimed to identify the clinical features of and treatment strategies for Chinese patients with bone metastases.MethodsConsecutive cancer patients who had bone metastases and received BP treatment were enrolled. A questionnaire was developed to collect the patients’ clinical data, as well as information on the diagnosis and management of bone metastases. Physicians’ awareness of the guidelines and knowledge of the application of BP were also assessed.ResultsA total of 3223 patients with lung cancer (36.5%), breast cancer (30.9%), prostate cancer (8.5%), and gastrointestinal cancer (5.7%) were included in this study. The sites of bone metastases were the thoracic spine (56.0 %), lumbar spine (47.1%), ribs (32.6%), and pelvis (23.2%). The SRE frequency was the highest in patients with multiple myeloma (36.6%), followed by those with lung cancer (25.9%), breast cancer (20.2%), prostate cancer (18.2%), and gastrointestinal cancer (17.3%). Irradiation to the bone was the most frequent SRE (58% in lung cancer patients, 45% in breast cancer patients, and 48% in prostate cancer patients). Our survey also showed that 45.5% of patients received BP within 3 months after their diagnosis of bone metastases, whereas the remaining 54.5% of patients did not receive BP treatment until at least 3 months after their diagnosis of bone metastases. The SRE frequency in the former group was significantly lower than that in the latter group (4.0% vs. 42.3%, P < 0.05). In patients with more than 6 months of continuous BP treatment, the mean time to the first SRE was significantly longer than that in patients with less than 6 months of continuous BP treatment (7.2 vs. 3.4 months, P < 0.05). In addition, 12.2% of the physicians were not aware of the efficacy of BP in preventing and delaying SRE. Only half (52.3%) of the physicians agreed that the BP treatment should persist for at least 6 months unless it was intolerable.ConclusionsOur study suggested that prompt and persistent BP treatment was associated with a reduced risk of SREs. However, our survey also revealed that the proper application of BP was not as common as expected in China.Electronic supplementary materialThe online version of this article (doi:10.1186/s40880-016-0102-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Yang

Jin

et al. 2016

Chin J Cancer

View full text Add to dashboard Cite

show abstract

“…Bisphosphonate (BP), an antiresorptive drug, acts as osteoclast function inhibitor which is led to decrease bone remodeling. [ 3 ] BP is effective against several conditions such as hypercalcemia of malignancy, multiple myeloma, and osteoporosis[ 4 5 ] in addition to skeletal-related events associated with metastatic bone disease along with solid tumors such as prostate, breast, lung cancers, and renal cell carcinoma. [ 6 ] The oral form of BP is used to treat osteoporosis, osteogenesis imperfecta, osteopenia in addition to Paget’s disease.…”

Section: Introductionmentioning

confidence: 99%

Knowledge, attitude, and management of general dentist toward medication-related osteonecrosis of the jaws

et al. 2020

View full text Add to dashboard Cite

A BSTRACT Background: Medication-related osteonecrosis of the jaw (MRONJ) is an intense negative drug response causing increasing bone destruction in the maxillofacial area of patients. Aims and Objectives: To evaluate the knowledge and attitude of dental practitioner regarding risk factors of MRONJ in Saudi Arabia. Materials and Methods: A cross-sectional, questionnaire survey was carried out in King Khalid Hospital, Al-Kharj among dental practioners. Results: Approximately 60% of the practioners had a poor knowledge and there was a weak positive correlation with work experience. Conclusion: Poor knowledge regarding the MRONJ invites a continuing dental education specially to focus on general practioners.

show abstract

“…[ 1 2 ] Intravenous (IV) bisphosphonates (BPs) are used in the treatment of cancer-related conditions as well as skeletal-related events associated with bone metastases, hypercalcemia of malignancy, and for the management of lytic lesion in the setting of multiple myeloma. [ 3 4 5 ] Oral BPs are used to manage condition including osteoporosis,[ 6 ] osteopenia,[ 7 ] osteogenesis imperfecta,[ 8 ] and Paget's disease. [ 9 ] RANK ligand inhibitor (denosumab) is an antiresorptive drug, which arrests the function of osteoclasts, reduces bone resorption, and intensifies bone density.…”

Section: Introductionmentioning

confidence: 99%

Dental students' knowledge of medication-related osteonecrosis of the jaw

et al. 2017

View full text Add to dashboard Cite

Objectives:The aim of this study was to evaluate and assess knowledge and attitude of dental students about medication-related osteonecrosis of the jaw (MRONJ), to optimize future training programs in this field.Materials and Methods:A cross-sectional study was administrated. Ninety-eight participants agreed to complete an anonymous questionnaire. It was divided into two sections: the first section was about general information such as interviewer's gender and date of birth; the second section included questions about bisphosphonates (BPs), others medication associated to osteonecrosis of the jaw (ONJ), risk factors, and prevention of osteonecrosis. Descriptive statistics were computed and the odds ratio was used to compare the odds for the groups.Results:Ninety-nine percent of participants declared to know BPs, but only 26.9% of 4th year and 34.8% of 6th year students knew the correct definition of MRONJ. Almost all of students identified the importance to report, in anamnesis, the use of BPs, as well as to check-up patients before the beginning of treatment; on the other hand, the knowledge about how invasive dental treatment might be carried out in patients under therapy was not adequate. In addition, half of the students did not recognize any active principle or commercial name of BPs. The situation was even worse regarding alternative drugs involved in ONJ.Conclusions:These findings are alarming and the lack of knowledge about MRONJ suggests that greater educational efforts should be performed about this pathology at undergraduate level.

show abstract

Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors

Abstract: Beyond 2 years of therapy, treatment patterns of ZOL were heterogeneous and SRE rates were low. The safety profile of ZOL was acceptable, and interrupting ZOL in patients with solid tumors was associated with a higher risk of SREs.

Cited by 19 publications

References 33 publications

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China

Knowledge, attitude, and management of general dentist toward medication-related osteonecrosis of the jaws

Dental students' knowledge of medication-related osteonecrosis of the jaw

Contact Info

Product

Resources

About